- Home
- ZVRA vs VSTM Comparison
ZVRA vs VSTM Comparison
Compare ZVRA & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVRA
- VSTM
- Stock Information
- Founded
- ZVRA 2006
- VSTM 2010
- Country
- ZVRA United States
- VSTM United States
- Employees
- ZVRA N/A
- VSTM N/A
- Industry
- ZVRA Biotechnology: Pharmaceutical Preparations
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- ZVRA Health Care
- VSTM Health Care
- Exchange
- ZVRA Nasdaq
- VSTM Nasdaq
- Market Cap
- ZVRA 400.8M
- VSTM 359.9M
- IPO Year
- ZVRA 2015
- VSTM 2012
- Fundamental
- Price
- ZVRA $8.01
- VSTM $7.16
- Analyst Decision
- ZVRA Strong Buy
- VSTM Strong Buy
- Analyst Count
- ZVRA 8
- VSTM 9
- Target Price
- ZVRA $22.29
- VSTM $13.13
- AVG Volume (30 Days)
- ZVRA 454.0K
- VSTM 1.3M
- Earning Date
- ZVRA 05-13-2025
- VSTM 05-20-2025
- Dividend Yield
- ZVRA N/A
- VSTM N/A
- EPS Growth
- ZVRA N/A
- VSTM N/A
- EPS
- ZVRA N/A
- VSTM N/A
- Revenue
- ZVRA $23,612,000.00
- VSTM $10,000,000.00
- Revenue This Year
- ZVRA $267.44
- VSTM $7.68
- Revenue Next Year
- ZVRA $90.10
- VSTM $605.06
- P/E Ratio
- ZVRA N/A
- VSTM N/A
- Revenue Growth
- ZVRA N/A
- VSTM N/A
- 52 Week Low
- ZVRA $4.20
- VSTM $2.10
- 52 Week High
- ZVRA $9.76
- VSTM $13.52
- Technical
- Relative Strength Index (RSI)
- ZVRA 60.10
- VSTM 60.04
- Support Level
- ZVRA $7.26
- VSTM $6.35
- Resistance Level
- ZVRA $8.10
- VSTM $8.00
- Average True Range (ATR)
- ZVRA 0.36
- VSTM 0.66
- MACD
- ZVRA 0.09
- VSTM 0.02
- Stochastic Oscillator
- ZVRA 91.45
- VSTM 58.69
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.